WO2021206467A1 - GLRB 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 - Google Patents
GLRB 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 Download PDFInfo
- Publication number
- WO2021206467A1 WO2021206467A1 PCT/KR2021/004411 KR2021004411W WO2021206467A1 WO 2021206467 A1 WO2021206467 A1 WO 2021206467A1 KR 2021004411 W KR2021004411 W KR 2021004411W WO 2021206467 A1 WO2021206467 A1 WO 2021206467A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- methylation
- gene
- colorectal
- glrb
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a composition, kit, nucleic acid chip and method capable of diagnosing colorectal cancer, rectal cancer or colorectal adenoma by detecting the methylation level of the CpG region of the GLRB gene.
- the large intestine is the last part of the digestive system, about 2m long, and is divided into the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum.
- Colorectal cancer is cancer occurring in this region and is mostly adenocarcinoma, and is largely divided into colon cancer and rectal cancer by region.
- Colorectal cancer can occur in any part of the colon/rectum, but it occurs most frequently in the rectum (about 40%), followed by the S colon, which is an office worker, with about 30%. Changes in dietary habits have significantly increased the incidence and mortality of colorectal cancer in Korea, and also act as a major cause of cancer-related deaths in the United States and Europe (American Cancer Society statics for 2009).
- the diagnosis of colorectal cancer is simply performed by performing a fecal occult blood test during a health examination. Although the examination is mainly performed through rectal examination, sigmoid colonoscopy, large intestine enema (barium enema), and colonoscopy, the prognosis varies greatly depending on the progress of the cancer at the time of diagnosis. Discovery is very important in improving patient survival.
- epigenetics is a field that studies the regulation of gene expression in a state in which the base sequence of DNA is not changed.
- Epigenetics studies the regulation of gene expression through epigenetic changes such as DNA methylation, acetylation of miRNAs or histones, methylation, phosphorylation and ubiquitination.
- Double DNA methylation is the most studied epigenetic mutation. Epigenetic mutations can result in gene function alterations and changes to tumor cells. Therefore, DNA methylation is associated with the expression (or inhibition and induction) of disease-regulating genes in cells, and recently, cancer diagnosis methods through DNA methylation measurement have been proposed. In particular, since cancer-specific methylation occurs in advance even in precancerous tissues, the detection of cancer-specific methylation is highly likely to be used for diagnosis of cancer.
- the present inventors found that a specific gene CpG region is in a hypermethylated state in colorectal cancer, rectal cancer or colorectal adenoma, and by detecting the methylation level, a composition, kit, which can diagnose colorectal cancer, rectal cancer or colon adenoma;
- the present invention was completed by developing a nucleic acid chip and method.
- compositions for diagnosing colorectal cancer, rectal cancer or colorectal adenoma comprising an agent for measuring the methylation level of a specific gene CpG region.
- Another object of the present invention is to provide a composition for diagnosing colorectal cancer, rectal cancer or colorectal adenoma, comprising an agent for measuring the methylation level of a specific gene CpG region.
- Another object of the present invention is to provide a composition for diagnosing colorectal cancer, rectal cancer or colorectal adenoma essentially consisting of an agent for measuring the methylation level of a specific gene CpG region.
- another object of the present invention is colon cancer, rectal cancer or colon containing a PCR primer pair for amplifying a fragment containing the CpG region of a specific gene and a sequencing primer for pyrosequencing the PCR product amplified by the primer pair
- a kit for diagnosing adenoma is provided.
- Another object of the present invention is to provide a nucleic acid chip for diagnosing colon cancer, rectal cancer or colorectal adenoma in which a probe capable of hybridization under stringent conditions with a fragment containing a CpG region of a specific gene is immobilized.
- Another object of the present invention is to measure the methylation level of a specific gene CpG region from a sample of an individual, and based on this, colorectal cancer, rectal cancer, or colorectal adenoma, comprising the step of determining whether colon cancer, rectal cancer or colorectal adenoma It is to provide a method for providing information for diagnosis.
- Another object of the present invention is to provide a use of a preparation for measuring the methylation level of the CpG region of the GLRB gene for preparing a preparation for diagnosing colorectal cancer, rectal cancer, or colon adenoma.
- compositions for diagnosing colon cancer, rectal cancer, or colon adenoma comprising an agent for measuring methylation level.
- the present invention also provides a composition for diagnosing colorectal cancer, rectal cancer, or colorectal adenoma, comprising an agent for measuring the methylation level of the CpG region of the GLRB gene.
- the present invention also provides a composition for diagnosing colorectal cancer, rectal cancer, or colorectal adenoma, which is essentially an agent for measuring the methylation level of the CpG region of the GLRB gene.
- the present invention provides a kit for diagnosing colon cancer, rectal cancer or colorectal adenoma, comprising a primer pair for amplifying a fragment including a CpG region of a GLRB gene.
- the present invention provides a nucleic acid chip for diagnosing colorectal cancer, rectal cancer or colorectal adenoma to which a probe capable of hybridization with a fragment containing the CpG region of the GLRB gene is immobilized. .
- the method comprising: measuring the methylation level of the CpG region of the GLRB gene from a sample of an individual suspected of having colorectal cancer, rectal cancer, or colorectal adenoma; and
- It provides a method of providing information for diagnosing colorectal cancer, rectal cancer or colorectal adenoma, including; determining whether colon cancer, rectal cancer, or colorectal adenoma is based on the measured methylation level.
- the present invention provides the use of an agent for measuring the methylation level of the CpG region of the GLRB gene for preparing a diagnostic agent for colorectal cancer, rectal cancer, or colorectal adenoma.
- It provides a method for diagnosing colorectal cancer, rectal cancer or colorectal adenoma, comprising c) determining whether or not colorectal cancer, rectal cancer, or colorectal adenoma is based on the measured methylation level.
- the present invention provides a composition for diagnosing colon cancer, rectal cancer, or colorectal adenoma, comprising an agent for measuring the methylation level of the CpG region of the GLRB gene.
- methylation refers to the attachment of a methyl group to a base constituting DNA.
- methylation refers to whether methylation occurs at a specific CpG site cytosine of a specific gene.
- methylation occurs, the binding of transcription factors is disturbed and the expression of a specific gene is suppressed.
- unmethylation or hypomethylation occurs, the expression of a specific gene is increased.
- 5-methylcytosine In the genomic DNA of mammalian cells, in addition to A, C, G, and T, there is a fifth base called 5-methylcytosine (5-mC) with a methyl group attached to the fifth carbon of the cytosine ring. do. 5-methylcytosine methylation occurs only at C of a CG dinucleotide called CpG (5'-mCG-3'), and CpG methylation inhibits expression of alu or transposon and genomic repeats. In addition, since 5-mC of CpG is easily deamidated to thymine (T), CpG is a site where most epigenetic changes frequently occur in mammalian cells.
- 5-mC of CpG is easily deamidated to thymine (T)
- T thymine
- the term “measuring methylation level” refers to measuring the methylation level of the CpG region of the GLRB gene, and may be measured by a bisulfite-treated detection method or a bisulfite-independent detection method.
- the measurement of methylation level can be performed by methylation-specific PCR, for example, methylation-specific polymerase chain reaction (MSP), real time methylation-specific polymerase chain reaction (PCR), methylated DNA-specific binding protein or It can be measured by PCR or quantitative PCR using a methylation sensitive restriction enzyme.
- MSP methylation-specific polymerase chain reaction
- PCR real time methylation-specific polymerase chain reaction
- methylated DNA-specific binding protein methylated DNA-specific binding protein
- the measurement may be performed by automatic sequencing such as pyrosequencing and bisulfite sequencing or next generation sequencing (NGS), but is not limited thereto.
- TET ten-eleven translocation protein
- the TET protein is an enzyme that acts on DNA and is involved in the chemical change of bases, and when treated with bisulfite, all Cs except for methylated C are changed to T bases, whereas in the TET protein, only methylated C is changed to T. Efficient detection is possible.
- the CpG region of the GLRB gene refers to a CpG region present on the DNA of the gene.
- the DNA of the gene is a concept including all of a series of structural units that are necessary for expression of the gene and are operably linked to each other, for example, a promoter region, a protein coding region (open reading frame, ORF) and a terminator. includes area.
- the CpG region of the GLRB gene may exist in a promoter region, a protein coding region (open reading frame, ORF) or a terminator region of the corresponding gene.
- measuring the methylation level of the CpG region of the GLRB gene in the present invention may mean measuring the level of cytosine methylation of the CpG region of the gene shown in Table 1 below.
- the CpG region of the GLRB gene is characterized in that it is located between +/- 2000 bases (2 kb) from the transcription start site (TSS) of the gene.
- the nucleotide sequence of the human genome chromosomal region is expressed according to The February 2009 Human reference sequence (GRCh37), but the specific sequence of the human genome chromosomal region may be slightly changed as the genomic sequence study results are updated. , the expression of the human genome chromosomal region of the present invention may be different according to this change. Therefore, the human genome chromosomal region expressed according to The February 2009 Human reference sequence (GRCh 37) of the present invention has been updated with the human reference sequence since the filing date of the present invention, so that the expression of the human genome chromosomal region is now Even if it is changed differently from , it will be apparent that the scope of the present invention extends to the altered human genome chromosomal region. These changes can be easily recognized by anyone with ordinary skill in the art to which the present invention pertains.
- the agent for measuring the methylation level of the CpG region is a compound that modifies a cytosine base or a methylation sensitive restriction enzyme, a primer specific for the methylated allele sequence of the GLRB gene, and a non-methylated allele sequence specific It may contain a specific primer.
- the compound that modifies the cytosine base is an unmethylated cytosine or a compound that modifies methylated cytosine, and bisulfite or a salt thereof that modifies unmethylated cytosine, preferably sodium bisulfite or a methylated cytosine is modified. It may be a TET protein, but is not limited thereto.
- a method for detecting whether a CpG site is methylated by modifying a cytosine base is well known in the art (WO01/26536; US2003/0148326A1).
- the methylation-sensitive restriction enzyme may be a restriction enzyme capable of specifically detecting methylation of a CpG site, and may be a restriction enzyme containing CG as a recognition site of the restriction enzyme. Examples include, but are not limited to, SmaI, SacII, EagI, HpaII, MspI, BssHII, BstUI, NotI, and the like. Depending on the methylation or unmethylation at C of the restriction enzyme recognition site, cleavage by the restriction enzyme changes, and it can be detected through PCR or Southern blot analysis. Methylation-sensitive restriction enzymes other than the above restriction enzymes are well known in the art.
- the primer may include a primer specific for the methylated allele sequence of the GLRB gene and a primer specific for the unmethylated allele sequence.
- primer refers to a short nucleic acid sequence that is capable of base pairing with a complementary template with a nucleic acid sequence having a short free 3' terminal hydroxyl group and serves as a starting point for template strand copying. . Primers are capable of initiating DNA synthesis in the presence of reagents for polymerization (ie, DNA polymerase or reverse transcriptase) and four different nucleoside triphosphates in appropriate buffers and temperatures. In addition, the primers may incorporate additional features that do not change the basic properties of the primers, which are sense and antisense nucleic acids with a sequence of 7 to 50 nucleotides, which serve as the starting point of DNA synthesis.
- the primer of the present invention can be preferably designed according to the sequence of a specific CpG site to be analyzed for methylation, and more preferably, can specifically amplify methylated and unmodified cytosine by bisulfite.
- the present invention provides a kit for diagnosing colon cancer, rectal cancer or colorectal adenoma, which includes a primer pair for amplifying a fragment containing the CpG region of the GLRB gene.
- composition and kit may further include a polymerase agarose, a buffer solution required for electrophoresis, and the like, in addition to the preparation.
- the present invention also provides a nucleic acid chip for diagnosing colorectal cancer, rectal cancer or colorectal adenoma to which a probe capable of hybridization with a fragment containing the CpG region of the GLRB gene is immobilized.
- nucleic acid means oligonucleotides, nucleotides, polynucleotides or fragments thereof, single- or double-stranded DNA or RNA of genomic or synthetic origin, sense or antisense strands of genomic origin or DNA of synthetic origin or RNA, PNA (peptide nucleic acid), or DNA or RNA-like substances of natural or synthetic origin. If the nucleic acid is RNA, it is obvious to one of ordinary skill in the art that instead of deoxynucleotides A, G, C and T, ribonucleotides A, G, C and U are substituted, respectively.
- the gene involved in cell transformation can be diagnosed early by detecting methylation outside the regulatory region.
- the methylation gene marker for early diagnosis of cells likely to form colorectal cancer, rectal cancer, or colorectal adenoma.
- a gene confirmed to be methylated in cancer cells is methylated in a cell that appears to be clinically or morphologically normal, the normal-looking cell is undergoing cancerization. Therefore, by confirming the methylation of a gene specific for colorectal cancer, rectal cancer, or colorectal adenoma in normal-looking cells, early diagnosis of colorectal cancer, rectal cancer, or colorectal adenoma can be achieved.
- the present invention comprises the steps of measuring the methylation level of the GLRB gene CpG region from a sample of an individual suspected of having colorectal cancer, rectal cancer, or colorectal adenoma;
- It provides a method of providing information for diagnosing colorectal cancer, rectal cancer or colorectal adenoma, including; determining whether colon cancer, rectal cancer, or colorectal adenoma is based on the measured methylation level.
- Methods for measuring the methylation level include PCR, methylation specific PCR, real time methylation specific PCR, PCR using a methylated DNA-specific binding protein, and methylation using a methylation sensitive restriction enzyme. , but may be selected from the group consisting of quantitative PCR, DNA chip, pyrosequencing and bisulfite sequencing, but is not limited thereto.
- methylation-specific PCR is a method of designing and using different types of primers depending on whether CpG dinucleotide is methylated as a primer to be subjected to PCR after treating sample DNA with bisulfite. am. If the primer binding site is methylated, PCR is performed by the methylated primer, and if not methylated, PCR is performed by the normal primer. That is, after treating the sample DNA with bisulfite, PCR is performed using two types of primers at the same time, and the results are compared.
- Real-time methylation-specific PCR is a conversion of a methylation-specific PCR method to a real-time measurement method. After genomic DNA is treated with bisulfite, PCR primers corresponding to methylation are designed, and real-time PCR is performed using these primers. is to perform At this time, there are two methods: a method of detecting using a TaqMan probe complementary to the amplified nucleotide sequence, and a method of detecting using SYBRgreen. Therefore, real-time methylation-specific PCR can selectively quantitatively analyze only methylated DNA. In this case, a standard curve is prepared using an in vitro methylated DNA sample, and for standardization, a gene without a 5'-CpG-3' sequence is amplified together as a negative control group to quantitatively analyze the degree of methylation.
- the methylation-sensitive restriction enzyme uses a CpG dinucleotide as an action site, and when this site is methylated, it cannot function as an enzyme. Therefore, if the sample DNA is treated with a methylation-sensitive restriction enzyme and amplified by PCR to include the enzyme target site, the restriction enzyme does not work in the case of methylation and is amplified by PCR, but the unmethylated normal site is cut by the restriction enzyme and PCR Since it is not amplified, it is possible to determine whether a specific DNA site is methylated.
- methylated DNA-specific binding protein when a protein that specifically binds only methylated DNA is mixed with DNA, only methylated DNA can be selectively isolated because the protein specifically binds only to methylated DNA. .
- genomic DNA After mixing genomic DNA with methylated DNA-specific binding protein, only methylated DNA is selectively isolated. This is a method of amplifying the isolated DNA using a PCR primer corresponding to the intron region, and measuring whether methylation is performed by agarose electrophoresis.
- methylation can be measured by quantitative PCR, and methylated DNA separated with a methylated DNA-specific binding protein is labeled with a fluorescent dye and hybridized to a DNA chip integrated with a complementary probe to measure methylation. can do.
- the methylated DNA specific binding protein is not limited to MBD2bt.
- pyrosequencing of bisulfite-treated DNA is based on the following principle.
- 5-methylcytosine (5-mC) is formed, which is changed to uracil upon bisulfite treatment.
- the DNA extracted from the sample is treated with bisulfite, if the CpG dinucleotide is methylated, it is conserved as cytosine, and the remaining unmethylated cytosine is changed to uracil.
- Sequencing of the bisulfite-treated DNA can be preferably performed using a pyrosequencing method.
- TET ten-eleven translocation
- the method for providing information for diagnosing colorectal cancer, rectal cancer or colorectal adenoma of the present invention comprises the steps of a) obtaining a sample from an individual, b) obtaining genomic DNA from the sample, c) the obtained genomic DNA Treating a compound that modifies an unmethylated cytosine base, d) amplifying the treated DNA by PCR using a pyrosequencing primer capable of amplifying the promoter of the GLRB gene to obtain a PCR product and e) measuring the degree of methylation by pyrosequencing the PCR product using a sequencing primer.
- the genomic DNA obtained in step b) can be performed using a phenol/chloroform extraction method, an SDS extraction method, a CTAB separation method, or a commercially available DNA extraction kit commonly used in the art.
- determining whether colorectal cancer, rectal cancer, or colorectal adenoma is based on the measured methylation level means measuring the methylation level of the CpG region of the GLRB gene from a sample of a patient suspected of having colorectal cancer, rectal cancer, or colorectal adenoma. It may be determined by simultaneously or sequentially measuring the methylation level of the CpG region of the same gene as above from a sample of a normal control group and then comparing the two.
- the determination may be made by measuring the methylation level of the CpG region of the GLRB gene in advance from a sample of a normal control group, setting a threshold value, and then comparing the threshold value with the value measured from the patient's sample. If the threshold value is set by measuring the methylation level of the CpG region of the GLRB gene from the sample of the normal control in advance, the methylation level of the CpG region of the GLRB gene is measured in the patient's sample without the need to measure the methylation level of the normal control each time for each diagnosis. It is possible to quickly provide information for diagnosing whether the patient has colorectal cancer, rectal cancer, or colorectal adenoma.
- sample refers to a wide range of body fluids, including all biological fluids obtained from individuals, body fluids, cell lines, tissue culture, etc., depending on the type of analysis to be performed.
- Methods for obtaining bodily fluids and tissue biopsies from mammals are generally well known, and in the present invention, the samples are preferably from the group consisting of tissues, cells, blood, plasma, serum, feces, and human derivatives including urine.
- the prediction of the occurrence of rectal cancer or colorectal adenoma there is an advantage in that it is possible to easily diagnose using blood or body fluids.
- the present invention provides the use of an agent for measuring the methylation level of the CpG region of the GLRB gene for preparing a diagnostic agent for colorectal cancer, rectal cancer or colorectal adenoma.
- It provides a method for diagnosing colorectal cancer, rectal cancer or colorectal adenoma, comprising c) determining whether or not colorectal cancer, rectal cancer, or colorectal adenoma is based on the measured methylation level.
- the present invention provides a method of diagnosing and treating colorectal cancer, rectal cancer or colorectal adenoma in an individual comprising the steps of:
- Step iv) is a step of performing treatment of the disease through means such as administration of a therapeutic drug or surgery to the individual diagnosed with the disease in step iii).
- the 'treatment' of the present invention refers generically to improving the symptoms of colorectal cancer, rectal cancer or colorectal adenoma or the disease, which may include curing, substantially preventing, or improving the condition of the disease. and alleviating, curing, or preventing one symptom or most symptoms resulting from colorectal cancer, rectal cancer or colorectal adenoma, but is not limited thereto.
- the 'therapeutic drug' is not particularly limited as long as it is a type of drug typically used for the treatment of colorectal cancer, rectal cancer, or colorectal adenoma.
- the therapeutic drug is administered to a subject in a 'therapeutically effective amount', and the therapeutically effective amount can be determined by those skilled in the art not only for the intrinsic properties of the drug, the route of administration and the number of treatments, but also the age, weight, health status, sex, and disease of the patient.
- the effective dosage for a patient can be determined by considering various factors such as the severity of the drug, diet, and excretion rate.
- the route of administration of the therapeutic drug is not particularly limited, and may be administered orally or parenterally, and includes both local administration as well as systemic administration.
- the parenteral administration is not limited thereto, but may be, for example, intranasal drug application, subcutaneous injection, or the like, and as another example, intramuscular injection, intravenous injection, etc. may be used.
- the 'sample' of the present invention is obtained by separating from a subject suspected of a disease, but is not limited thereto, but is not limited to cells, tissues, blood, serum, plasma, saliva, and sputum. It may be selected from the group consisting of mucosal fluid and urine, and the 'individual' may be an animal, preferably a mammal, particularly an animal including a human, and may be an animal-derived cell, tissue, organ, or the like. The subject may be a patient in need of the therapeutic effect.
- the term “comprising” is used synonymously with “including” or “characterized by”, and in a composition or method according to the present invention, specifically It does not exclude additional components or method steps that have not been performed. Also, the term “consisting of” means excluding additional elements, steps, or components not otherwise described. The term “essentially consisting of” means that, in the scope of a composition or method, it may include substances or steps that do not materially affect its basic properties in addition to the substances or steps described.
- hypermethylation of the CpG region of the GLRB gene is specifically shown in colorectal cancer, rectal cancer, or colorectal adenoma. It can be diagnosed accurately and quickly, and can be diagnosed at an early stage.
- 1 is a result of confirming the methylation information of the GLRB gene in a total of 32 cancer types.
- cancer tumor tissue
- adenoma colorectal adenoma tissue
- normal tissue normal
- FIG. 6 is a comparative example, showing the results of confirming the methylation information of the OPLAH gene.
- ddPCR droplet digital PCR
- ddPCR droplet digital PCR
- Example 1 Colorectal cancer-specific methylation gene selection
- Tumor tissue used in this study means cancerous tissue of colorectal cancer
- non-tumor tissue means tissue other than cancer tissue including normal tissue.
- DNA extracted from each tissue is converted through bisulfite treatment. Through this, the cytosine base is modified depending on whether the DNA site is methylated.
- the probe used in the microarray experiment was specifically designed for methylation and unmethylation to check whether the cytosine base was modified at the gene methylation site.
- the microarray experiment measures the degree of methylation of a gene through about 450,000 (450k) probes representing the methylation site of each gene, and the result of each probe derived from the test is presented as a beta value. .
- the beta value ranges from 0 to 1, and the closer to 1, the higher the degree of methylation of the genetic region.
- DMRs differentially methylated regions
- the Limma method is known to be the least affected by outliers among several methylation statistical analysis methods that identify differences between groups. Therefore, it is a suitable method for finding cancer-specific markers as it is less affected by abnormal measurements of some samples. In this experiment, it was determined that there was a significant difference in methylation between the two groups as the adjusted p-value derived through the Limma method decreased.
- tumor-specific methylation sites among gene regions with significant beta differences between tumor and non-tumor groups, sites with higher methylation in tumor tissues than in non-tumors were selected as cancer-specific biomarker candidates.
- the tumor group had a significantly lower p value (the top 10% with the lowest P value), and a large difference in the beta value of 0.2 or more between the groups was found in the gene region.
- Tumor-specific hypermethylated regions were selected. Through this, 3,878 genetic regions showing tumor-specific hypermethylation in common among all datasets among about 450,000 genetic regions were selected as biomarker candidates.
- the degree of methylation of the gene through the microarray experiment on tumor tissue (cancer tissue of colorectal cancer) and non-tumor tissue (tissue other than cancer tissue including normal tissue) for the gene is shown in FIG. 1 same as As for the degree of methylation, the result of each probe derived through the test was expressed as a beta value.
- the beta value ranges from 0 to 1, and the closer to 1, the higher the degree of methylation of the genetic region.
- methylation may also occur in cancers other than colorectal cancer, rectal cancer, or colorectal adenoma. That is, colorectal cancer, rectal cancer, or colorectal adenoma-specific methylation was not confirmed.
- OPLAH 5-oxoprolinase, ATP-hydrolysing
- the 32 types of cancer are as follows: Acute Myeloid Leukemia, Adrenocortical cancer, Bile Duct cancer, Breast cancer, Cervical Cancer, Colorectal cancer Colon cancer, Endometrioid Cancer, Esophageal Cancer, Glioblastoma, Head and neck cancer, Kidney chromophobe, Kidney Clear cell carcinoma), Kidney Papillary cell carcinoma, Liver cancer, Lower Grade Glioma, Lung adenocarcinoma, Melanoma, Mesothelioma, ocular melanoma Ocular melanomas, Ovarian cancer, Pancreatic cancer, Pheochromocytoma¶ganglioma, Prostate cancer, Rectal cancer, Sarcoma, Stomach cancer, testicular cancer, Thymoma, Thyroid cancer, Uterine carcinosarcoma.
- Example 3 Confirmation of colorectal cancer specificity of a selection gene in a cell line
- methylation patterns were analyzed in 1,022 cancer cell lines derived from 14 major tissues using a public database. did. The data is the result of the Infinium Human Methylation 450 Beadchip microarray experiment on DNA extracted from each cell line according to the standardized manufacturer's methylation analysis test procedure.
- the degree of gene methylation is measured through about 450,000 probes as in Example 1, and the methylation value of each probe is presented as a beta value.
- the beta value ranges from 0 to 1, and the closer to 1, the higher the degree of methylation of the genetic region is determined.
- the 14 tissues are as follows: aerodigestive tract, blood, bone, breast, digestive system, kidney, lung, nervous system ( nervous system, pancreas, skin, soft tissue, thyroid, urogenital system, other tissues.
- DMRs differentially methylated regions
- Limma Linear Models for Microarray Data
- the GLRB gene is colorectal cancer-specific as it has a significantly lower adjusted p-value in colorectal and rectal cancer cell lines compared to other cancer cell lines.
- Example 4 Evaluation of diagnostic performance of colorectal cancer, rectal cancer or colorectal adenoma diagnostic marker candidates
- sensitivity and specificity are used. It is possible to represent the ROC (Receiver Operating Characteristic) curve that presents the change in sensitivity and specificity according to the cut-off value through the calculation of the sensitivity and specificity values for possible cut-off values of consecutive diagnostic test measurements. have.
- the accuracy of diagnosis can be measured by the area under the ROC curve (AUC).
- AUC area under the ROC curve
- the AUC value has a value between 0.5 and 1, and the higher the value, the higher the diagnosis accuracy is evaluated. If the AUC value is 1, it means that the diagnosis result is a perfectly accurate test, but if the AUC value is 0.5, it is judged to be the same as the random result.
- Adenoma is a disease at the stage before it progresses to colorectal cancer, and most colorectal cancers arise from adenoma. Therefore, early detection of adenoma is essential for early diagnosis of colorectal cancer.
- the hypermethylation biomarkers selected through the previous study show hypermethylation characteristics in adenomas, 64 colorectal cancer tissues, 42 colorectal adenoma tissues, and non-tumor The hypermethylation characteristics of genes selected from 41 tumor) tissues were investigated.
- the selected gene showed the same characteristics of non-tumor tissue and significant hypermethylation in colorectal cancer as well as colorectal adenoma. could confirm that
- the selected gene can be used for the diagnosis of colorectal adenoma as well as colorectal cancer.
- Example 6 qMSP-based methylation measurement in tissues of selected genes
- a methylation difference between cancer tissues and non-cancer tissues was measured using methylation-specific PCR (quantitative methylation specific PCR, qMSP).
- genomic DNA was isolated from a pair of cancer tissues and surrounding tissues of 12 colorectal cancer patients and cancer tissues of 4 adenoma patients. The degree of amplification and methylation was to be observed.
- the ACTB gene which is not related to methylation, was used to specifically bind to and amplify the bisulfite-modified genetic region, and to normalize the amplified value of the region.
- ⁇ Ct The methylation level of the bisulfite-converted DNA amplified by PCR is expressed as ⁇ Ct, which is a value corrected by the Ct (Cycle of Threshold) value of ACTB used as an internal control.
- ⁇ Ct is defined as:
- ⁇ Ct Ct value of the ACTB gene - Ct value of the gene to be detected
- methylation of the GLRB gene has a relatively high ⁇ Ct value regardless of the stage in colorectal cancer tissue compared to normal tissue surrounding the cancer, and in particular, a very high ⁇ Ct value in precancerous adenoma. It was confirmed that the GLRB gene was hypermethylated in colorectal cancer and colorectal adenoma. This is a result that actually shows that methylation of the selected GLRB gene is effective as a biomarker for the diagnosis of colorectal cancer, especially early diagnosis.
- the selected gene can be used for the diagnosis of colorectal adenoma as well as colorectal cancer.
- Example 7 Measurement of methylation based on digital PCR in tissues of selected genes
- genomic DNA was isolated from the cancer tissues of 16 colorectal cancer patients, pairs of cancer surrounding tissues (4 pairs by stage), and cancer tissues of 5 adenoma patients, and after treatment with bisulfite, droplet digital PCR (Droplet digital PCR, ddPCR) was used to observe amplification and methylation levels of GLRB-specific gene regions.
- the ACTB gene was used as an internal control for the modification of the genetic region due to bisulfite and the amplification of the genetic region using PCR.
- the degree of methylation obtained by amplifying the bisulfite-converted cfDNA by ddPCR was calculated as the number of copies.
- methylation of the GLRB gene has a relatively high copy number irrespective of the stage in colorectal cancer tissue compared to normal tissue surrounding the cancer, and in particular, it shows a very high copy number in the precancerous stage adenoma.
- PCR it was confirmed that the GLRB gene was hypermethylated in colorectal cancer and colorectal adenoma. This result shows that methylation of the selected GLRB gene can be effectively detected not only by real-time PCR but also by digital PCR.
- the selected gene can be diagnosed using various molecular biological techniques.
- methylation of the GLRB gene showed a high methylation level in colorectal cancer plasma samples compared to normal subjects, and it was shown that it could be measured with 100% accuracy. This result shows that methylation of the selected GLRB gene is effective for the diagnosis of tissue as well as blood-based colorectal cancer.
- composition, kit, chip or method according to the present invention is used to accurately and Not only can it be diagnosed quickly, but it can also be diagnosed early.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Symbol | Genome Build | Chromosome | Region |
GLRB | GRCh37 | 4 | 157997167-157997686 |
dataset#1 | dataset#2 | 총합 | |
종양
(tumor) |
112개 | 395개 | 507개 |
비종양
(non-tumor) |
149개 | 45개 | 194개 |
Symbol | Name |
Location
(Chromosome) |
CpG Island |
GLRB | glycine receptor beta | 4 | Island |
Symbol |
Difference
(average Δβ) |
adjusted p-value |
GLRB | 0.65 | 7.05e-31 |
Claims (12)
- GLRB 유전자 CpG 부위의 메틸화 수준을 측정하는 제제를 포함하는 대장암, 직장암 또는 대장 선종 진단용 조성물.
- 제1항에 있어서,상기 CpG 부위는 유전자의 전사 시작 부위로부터 +/- 2000 염기(base) (2kb) 사이에 위치하는 것을 특징으로 하는 조성물.
- 제1항에 있어서,상기 유전자 CpG 부위의 메틸화 수준을 측정하는 제제는 비메틸화 사이토신 또는 메틸화 사이토신 염기를 변형시키는 화합물;GLRB 유전자 CpG 부위의 메틸화된 서열에 특이적인 프라이머; 및비메틸화된 서열에 특이적인 프라이머로 이루어진 군에서 선택되는 것을 특징으로 하는 조성물.
- 제3항에 있어서,상기 비메틸화 사이토신 염기를 변형시키는 화합물은 바이설파이트(bisulfite), 이의 염이며, 상기 메틸화 사이토신 염기를 변형시키는 화합물은 TET 단백질인 것을 특징으로 하는 조성물.
- 제 1항에 있어서,상기 메틸화 수준의 측정은 바이설파이트 비의존적 (bisulfite-free) 검출법, 메틸화 특이적 중합효소반응(methylation-specific polymerase chain reaction), 실시간 메틸화 특이적 중합효소반응(real time methylation-specific polymerase chain reaction), 메틸화 DNA 특이적 결합 단백질 또는 메틸화 민감 제한효소 (methylation sensitive restriction enzyme)을 이용한 PCR, 정량 PCR, 파이로시퀀싱 및 바이설파이트 시퀀싱 및 차세대염기서열분석(Next Generation Sequencing, NGS)으로 이루어진 군에서 선택되는 것을 특징으로 하는 조성물
- GLRB 유전자의 CpG 부위를 포함하는 단편을 증폭하기 위한 프라이머쌍을 포함하는 대장암, 직장암 또는 대장 선종 진단용 키트.
- GLRB 유전자의 CpG 부위를 포함하는 단편과 혼성화(hybridization)할 수 있는 프로브가 고정되어 있는 대장암, 직장암 또는 대장 선종 진단용 핵산 칩.
- 대장암, 직장암 또는 대장 선종 발생이 의심되는 개체의 시료로부터 GLRB 유전자의 CpG 부위의 메틸화 수준을 측정하는 단계; 및상기 측정된 메틸화 수준을 기준으로 대장암, 직장암 또는 대장 선종 여부를 판단하는 단계;를 포함하는, 대장암, 직장암 또는 대장 선종 진단을 위한 정보를 제공하는 방법.
- 제8항에 있어서,상기 메틸화 수준을 측정하는 방법은 바이설파이트 비의존적 (bisulfite-free) 검출법, 메틸화 특이적 중합효소반응(methylation-specific polymerase chain reaction), 실시간 메틸화 특이적 중합효소반응(real time methylation-specific polymerase chain reaction), 메틸화 DNA 특이적 결합 단백질 또는 메틸화 민감 제한효소 (methylation sensitive restriction enzyme)을 이용한 PCR, 정량 PCR, 파이로시퀀싱 및 바이설파이트 시퀀싱 및 차세대염기서열분석(Next Generation Sequencing, NGS)으로 이루어진 군에서 선택되는 것인 방법.
- 제8항에 있어서,상기 시료는 조직, 세포, 혈액, 혈장, 혈청, 대변 및 소변으로 구성된 군에서 선택되는 것을 특징으로 하는 방법.
- 대장암, 직장암 또는 대장 선종 진단용 제제를 제조하기 위한 GLRB 유전자 CpG 부위의 메틸화 수준을 측정하는 제제의 용도.
- a) 개체로부터 시료를 수득하는 단계;b) 상기 시료로부터 GLRB 유전자 CpG 부위의 메틸화 수준을 측정하는 단계; 및c) 상기 측정된 메틸화 수준을 기준으로 대장암, 직장암 또는 대장 선종 여부를 판단하는 단계;를 포함하는 대장암, 직장암 또는 대장 선종 진단 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21783723.6A EP4134453A4 (en) | 2020-04-08 | 2021-04-08 | COMPOSITION FOR THE DIAGNOSIS OF COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA WITH CPG METHYLATION ALTERATION OF THE GIRB GENE AND USE THEREOF |
JP2022562018A JP2023521799A (ja) | 2020-04-08 | 2021-04-08 | GLRB遺伝子のCpGメチル化の変化を利用した結腸癌、直腸癌、又は大腸腺腫診断用組成物、及びその使用 |
US17/995,685 US20230132750A1 (en) | 2020-04-08 | 2021-04-08 | Composition for diagnosing colorectal cancer, rectal cancer, or colorectal adenoma using cpg methylation change of glrb gene, and use thereof |
AU2021252396A AU2021252396A1 (en) | 2020-04-08 | 2021-04-08 | Composition for diagnosing colorectal cancer, rectal cancer, or colorectal adenoma using cpg methylation change of glrb gene, and use thereof |
CN202180039764.XA CN115698340A (zh) | 2020-04-08 | 2021-04-08 | 用glrb基因cpg甲基化变化来诊断结直肠癌、直肠癌或结直肠腺瘤的组合物和其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0042726 | 2020-04-08 | ||
KR20200042726 | 2020-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021206467A1 true WO2021206467A1 (ko) | 2021-10-14 |
Family
ID=78022764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/004411 WO2021206467A1 (ko) | 2020-04-08 | 2021-04-08 | GLRB 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230132750A1 (ko) |
EP (1) | EP4134453A4 (ko) |
JP (1) | JP2023521799A (ko) |
KR (1) | KR20210125442A (ko) |
CN (1) | CN115698340A (ko) |
AU (1) | AU2021252396A1 (ko) |
WO (1) | WO2021206467A1 (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026536A2 (en) | 1999-10-13 | 2001-04-19 | The Johns Hopkins University School Of Medicine | Methods of diagnosing and treating hepatic cell proliferative disorders |
US20030148326A1 (en) | 2000-04-06 | 2003-08-07 | Alexander Olek | Diagnosis of diseases associated with dna transcription |
WO2007132883A1 (ja) * | 2006-05-17 | 2007-11-22 | Yokohama City University | 肝臓癌の鑑別、疾患ステージの判定又は予後の予測方法及びキット |
WO2007149269A2 (en) * | 2006-06-12 | 2007-12-27 | Oncomethylome Sciences S.A. | Methylation markers for early detection and prognosis of colon cancers |
KR20140121522A (ko) * | 2013-04-05 | 2014-10-16 | 연세대학교 산학협력단 | 국소 진행형 위암에 대한 예후 예측 시스템 |
KR101794328B1 (ko) * | 2016-03-09 | 2017-11-06 | 아주대학교산학협력단 | 794개 유전자 세트를 포함하는 간내담도암 예후 예측용 바이오마커 조성물 |
JP2018500933A (ja) * | 2014-12-19 | 2018-01-18 | エピゲノミクスアーゲー | CpGメチル化の検出方法及び癌の診断方法 |
KR20200042726A (ko) | 2018-10-16 | 2020-04-24 | 현대위아 주식회사 | 차량용 오일필터 체결기구 |
-
2021
- 2021-04-08 JP JP2022562018A patent/JP2023521799A/ja active Pending
- 2021-04-08 US US17/995,685 patent/US20230132750A1/en active Pending
- 2021-04-08 CN CN202180039764.XA patent/CN115698340A/zh active Pending
- 2021-04-08 KR KR1020210046009A patent/KR20210125442A/ko not_active Application Discontinuation
- 2021-04-08 EP EP21783723.6A patent/EP4134453A4/en active Pending
- 2021-04-08 WO PCT/KR2021/004411 patent/WO2021206467A1/ko unknown
- 2021-04-08 AU AU2021252396A patent/AU2021252396A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026536A2 (en) | 1999-10-13 | 2001-04-19 | The Johns Hopkins University School Of Medicine | Methods of diagnosing and treating hepatic cell proliferative disorders |
US20030148326A1 (en) | 2000-04-06 | 2003-08-07 | Alexander Olek | Diagnosis of diseases associated with dna transcription |
WO2007132883A1 (ja) * | 2006-05-17 | 2007-11-22 | Yokohama City University | 肝臓癌の鑑別、疾患ステージの判定又は予後の予測方法及びキット |
WO2007149269A2 (en) * | 2006-06-12 | 2007-12-27 | Oncomethylome Sciences S.A. | Methylation markers for early detection and prognosis of colon cancers |
KR20140121522A (ko) * | 2013-04-05 | 2014-10-16 | 연세대학교 산학협력단 | 국소 진행형 위암에 대한 예후 예측 시스템 |
JP2018500933A (ja) * | 2014-12-19 | 2018-01-18 | エピゲノミクスアーゲー | CpGメチル化の検出方法及び癌の診断方法 |
KR101794328B1 (ko) * | 2016-03-09 | 2017-11-06 | 아주대학교산학협력단 | 794개 유전자 세트를 포함하는 간내담도암 예후 예측용 바이오마커 조성물 |
KR20200042726A (ko) | 2018-10-16 | 2020-04-24 | 현대위아 주식회사 | 차량용 오일필터 체결기구 |
Non-Patent Citations (7)
Title |
---|
"THE CAMBRIDGE DICTIONARY OF SCIENCE AND TECHNOLOGY", 1988 |
LIU, YIBIN ET AL., NATURE BIOTECHNOLOGY, vol. 37, 2019, pages 424 - 429 |
NYR, P, METHODS MOL BIOLOGY, vol. 373, 2007, pages 114 |
RONAGHI ET AL., ANALYTICAL BIOCHEMISTRY, vol. 242, no. 1, 1 November 1996 (1996-11-01), pages 84 - 9 |
RONAGHI ET AL., ANALYTICAL BIOCHEMISTRY, vol. 286, no. 2, 15 November 2000 (2000-11-15), pages 282 - 288 |
RONAGHI ET AL., SCIENCE, vol. 281, no. 5375, 17 July 1998 (1998-07-17), pages 363 - 365 |
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOTY", 1994 |
Also Published As
Publication number | Publication date |
---|---|
CN115698340A (zh) | 2023-02-03 |
US20230132750A1 (en) | 2023-05-04 |
EP4134453A4 (en) | 2024-06-26 |
AU2021252396A1 (en) | 2022-11-17 |
JP2023521799A (ja) | 2023-05-25 |
KR20210125442A (ko) | 2021-10-18 |
EP4134453A1 (en) | 2023-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011055916A2 (ko) | 장암 진단을 위한 장암 특이적 메틸화 마커 유전자의 메틸화 검출방법 | |
WO2014073785A1 (ko) | 위용종 및 위암 특이적 메틸화 마커 유전자를 이용한 위용종 및 위암의 검출방법 | |
WO2021075797A2 (ko) | 특정 유전자의 cpg 메틸화 변화를 이용한 간암 진단용 조성물 및 이의 용도 | |
WO2009113771A1 (ko) | 폐암특이적 메틸화 마커 유전자를 이용한 폐암 검출방법 | |
WO2012070861A2 (ko) | 위암 진단을 위한 위암 특이적 메틸화 바이오마커 | |
WO2022075788A1 (ko) | LINC01798 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 | |
WO2015023146A1 (ko) | 전암병변의 검출방법 | |
US20100068720A1 (en) | Method and kit for detection of early cancer or pre-cancer using blood and body fluids | |
WO2012081928A2 (ko) | 장암 진단을 위한 장암 특이적 메틸화 마커 gpm6a 유전자의 메틸화 검출방법 | |
WO2014027831A1 (ko) | 방광암 예후 진단 마커 | |
CN105026580A (zh) | 重亚硫酸盐转化的核苷酸序列的检测 | |
WO2021154009A1 (ko) | 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도 | |
WO2014168346A1 (ko) | 방광암 특이적 후성유전적 마커 유전자를 이용한 방광암의 검출방법 | |
WO2011132989A2 (ko) | 자궁경부암 진단용 메틸화 마커 | |
WO2016108403A1 (ko) | 방광암 예후 진단 마커로서 rsph9의 용도 | |
WO2021206467A1 (ko) | GLRB 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 | |
KR20210044441A (ko) | 특정 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도 | |
US20130095477A1 (en) | Non-Invasive Method for the Early Detection of Stomach Cancer | |
KR100617649B1 (ko) | 대장암 특이적 발현감소 유전자의 메틸화된 프로모터를 함유하는 암 진단용 조성물 및 그 용도 | |
WO2018194280A1 (ko) | SDC2(Syndecan 2) 유전자의 메틸화 검출방법 | |
WO2023132626A1 (ko) | 특정 유전자의 cpg 메틸화 변화를 이용한 전립선암 진단용 조성물 및 이의 용도 | |
WO2021167413A1 (ko) | 핵산의 메틸화 차이를 이용한 마커 선별방법, 메틸 또는 탈메틸 마커 및 이 마커를 이용한 진단방법 | |
WO2011049322A2 (ko) | 유방암 진단을 위한 유방암 특이적 메틸화 마커 유전자의 메틸화 검출방법 | |
WO2024090805A1 (ko) | 폐암 진단용 메틸화 마커 및 이의 조합 | |
WO2022216125A1 (ko) | Dna 메틸화 마커 검출을 이용한 비알코올성 지방간 질환 진단용 조성물 및 이의 활용 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21783723 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022562018 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021783723 Country of ref document: EP Effective date: 20221108 |
|
ENP | Entry into the national phase |
Ref document number: 2021252396 Country of ref document: AU Date of ref document: 20210408 Kind code of ref document: A |